MBAI Overview

Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.

Wall Street analysts forecast MBAI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBAI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Check Cap Ltd revenue for the last quarter amounts to -4.08M USD, decreased -3.08

Check Cap Ltd. EPS for the last quarter amounts to -3539000.00 USD, decreased -16.49

Check Cap Ltd (MBAI) has 0 emplpoyees as of March 30 2026.

Today MBAI has the market capitalization of 11.95M USD.